14636-28-3

Upstream product

• 211918-52-4 6,6-diphenyl-hex-5-enoic acid methyl ester 
• 14636-27-2 6,6-diphenylhex-5-enenitrile 
• 71-43-2 benzene 
• 21876-11-9 6-oxo-6-phenyl-hexanoic acid methyl ester 
• 35444-44-1 methyl adipoyl chloride 
• 4509-90-4 5-bromovaleroyl chloride 
• 119-61-9 benzophenone 
• 17814-85-6 (4-carboxybutyl)triphenylphosphonium bromide 
• 74412-93-4 methyl 6,6-diphenyl-6-hydroxyhexanoate 

Downstream Products

• 109252-38-2 6,6-Diphenyl Hexanoic Acid 
• 339314-69-1 S-(2-methoxycarbonyl)phenyl 6,6-diphenyl-5-hexenethioate 
• 181580-91-6 3-methoxy-8,8-diphenyl-7-octenoic acid 
• 181580-93-8 2,3-dimethoxy-8,8-diphenyl-7-octenoic acid 
• 181580-87-0 3-Methoxy-8,8-diphenyl-oct-7-enoic acid 2-thioxo-2H-pyridin-1-yl ester 
• 181580-89-2 2,3-Dimethoxy-8,8-diphenyl-oct-7-enoic acid 2-thioxo-2H-pyridin-1-yl ester 
• 169138-21-0 6,6-diphenyl-5-hexene-1-ol 
• 30614-37-0 2-(diphenylmethyl)cyclopentanone 

Relevant academic research and scientific papers

A Visible-Light-Driven Iminyl Radical-Mediated C?C Single Bond Cleavage/Radical Addition Cascade of Oxime Esters

A room-temperature, visible-light-driven N-centered iminyl radical-mediated and redox-neutral C?C single bond cleavage/radical addition cascade reaction of oxime esters and unsaturated systems has been accomplished. The strategy tolerates a wide range of O-acyl oximes and unsaturated systems, such as alkenes, silyl enol ethers, alkynes, and isonitrile, enabling highly selective formation of various chemical bonds. This method thus provides an efficient approach to various diversely substituted cyano-containing alkenes, ketones, carbocycles, and heterocycles.

N-Heterocyclic Carbene Iron(III) Porphyrin-Catalyzed Intramolecular C(sp3)–H Amination of Alkyl Azides

Metal-catalyzed intramolecular C?H amination of alkyl azides constitutes an appealing approach to alicyclic amines; challenges remain in broadening substrate scope, enhancing regioselectivity, and applying the method to natural product synthesis. Herein we report an iron(III) porphyrin bearing axial N-heterocyclic carbene ligands which catalyzes the intramolecular C(sp3)–H amination of a wide variety of alkyl azides under microwave-assisted and thermal conditions, resulting in selective amination of tertiary, benzylic, allylic, secondary, and primary C?H bonds with up to 95 % yield. 14 out of 17 substrates were cyclized selectively at C4 to give pyrrolidines. The regioselectivity at C4 or C5 could be tuned by modifying the reactivity of the C5–H bond. Mechanistic studies revealed a concerted or a fast re-bound mechanism for the amination reaction. The reaction has been applied to the syntheses of tropane, nicotine, cis-octahydroindole, and leelamine derivatives.

Selenium-catalyzed regioselective cyclization of unsaturated carboxylic acids using hypervalent iodine oxidants

A new and convenient selenium-catalyzed regioselective cyclization of γ, δ-unsaturated carboxylic acids to the corresponding 3, 6-dihydro-2Hpyran- 2-ones is described. The cyclization products have been obtained in good to excellent yields using diphenyl diselenide as a catalyst and [bis(trifluoroacetoxy)iodo]benzene as a stoichiometric oxidant 2011 American Chemical Society.

Preferentially substituted calcium channel blockers

Compounds of the formula and their salts, wherein Cy represents cyclohexyl; Y is CH═CHΦ, CHΦ2, Φ or Cy, X is trivalent straight-chain alkylene (3-10C) or trivalent straight-chain 1-alkenylene (3-10C) optionally substituted by oxo at the C adjacent N when n is 0 and Y is Φ2CH; and is otherwise trivalent straight-chain alkylene (5-10C) or trivalent straight-chain 1-alkenylene (5-10C) optionally substituted by oxo at the C adjacent N; Z is N, NCO, CHNCOR1or CHNR1, wherein R1is alkyl (1-6C); and n is 0-5; wherein each Φ and Cy independently may optionally be substituted by alkyl (1-6C) or by halo, CF3, OCF3, NO2, NR2, OR, SR, COR, COOR, CONR2, NROCR or OOCR where R is H or alkyl (1-4C), or two substituents may form a 5-7 membered ring with the proviso that the compounds of formula (1) contain at least one aromatic moiety, are useful as calcium channel blockers.

Calcium channel blockers

Compounds of the formula wherein m is 0, 1 or 2; wherein when m is O, Z is O, when m is 1, Z is N, and when m is 2, Z is C; Y is H, OH, NH2, or an organic moiety of 1-20C, optionally additionally containing 1-8 heteaoms selected from te group consisting of N, P, O, S and halo; each 11and 2 is independently 0-5; 13is 0 or 1; each of R1, R2and R3is independently alkyl (1-6C), aryl (6-10C) or arylalkyl (7-16C) optionally containing 14 heteroatoms selected from the group consisting of halo, N, P, O, and S or each of R1and R2may independently be halo, COOR, CONR2, CF3, CN or NO2, wherein R is H or lower alkyl (1-4C) or alkyl (1-6C); n is 0 or 1; X is a linker, with the proviso that Y is not a tropolone, a coumarin, or an antioxidant containing an aromatic group and with the further proviso that if 13 is 0, neither R′ nor R2can represent F in the para position; and are useful as calcium channel blockers. Libraries of these compounds can also be used to identify antagonists for other targets.

Polar substituent and solvent effects on the kinetics of radical reactions with thiols

The rates of thiol trapping of radicals depend upon polar substituents and solvent effects. The rate accelerating effect of water on the reactions of biologically relevant radicals is of special importance.

Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors

The invention relates to compounds of the formula STR1 wherein Y and Y' are hydrogen or taken together are O or S, *A is paraphenylene or *----(CH2)n --(X)s --(CH2)r ----, X is O, S or --CH=CH--, n or r, independently, are integers from 0 to 3, m is an integer from 0 to 1, s is an integer from 0 to 1, provided that when s is 1, n+m must be at least 2, t is an integer from 0 to 10, R1 and R2, independently, are lower alkyl, lower alkenyl or aryl, or one of R1 or R2 is hydrogen and the other is STR2 wherein W is STR3 --CH2 --CH2 --, --CH2 --, O, S, or STR4 and X1 is lower alkyl, phenyl unsubstituted or mono-, di- or trisubstituted by lower alkoxy, lower alkyl or halogen, and X2, X3 and X4, independently, are hydrogen, lower alkyl, lower alkoxy or halogen, R3 is hydrogen, lower alkyl or aryl, R4 is hydrogen, lower alkyl, aryl, aryl-lower alkyl or acyl, R5 is hydrogen or lower alkyl, R6 is hydrogen, lower alkyl, cycloalkyl, Het-lower alkyl or aryl, Het is a monocyclic 6-membered heteroaromatic radical containing one or two nitrogen atoms, which radical may be substituted by lower alkyl, halogen or aryl, and the asterisk denotes the point of attachment, and when R5 and R6 are different, their enantiomers and racemic mixtures thereof, when R1 and R2 are different, their geometric isomers, and pharmaceutically acceptable acid addition salts thereof.

Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor

A series of N-[4-(3-pyridinyl)butyl]-5,5-disubstituted-pentadienamides was prepared and evaluated for PAF-antagonist activity. Compounds were assayed in vitro in a PAF-binding assay employing washed, whole dog platelets as the receptor source and in vivo after intravenous or oral administration for their ability to prevent PAF-induced bronchoconstriction in guinea pigs. Criteria required for good oral activity in the latter model include an (E,E)-5-phenyl-2,4-pentadienamide, a second phenyl or a four- or five-carbon alkyl moiety in the 5-position of the diene, and an (R)-[1-alkyl-4-(3-pyridinyl)butyl] substituent on the carboxamide nitrogen atom. The alkyl substituent on this side chain can be methyl, ethyl, or cyclopropyl. Two members of this series, [R-(E)]-5,5-bis(4-methoxyphenyl)-N-[1-methyl-4-(3-pyridinyl)butyl]-2,4- pentadienamide (31) and [R-(E,E)]-5-(4-methoxyphenyl)-N-[1-methyl-4-(3-pyridinyl)butyl]-2,4- decadienamide (58), were selected for further pharmacological evaluation. Both were found to be substantially longer acting after oral administration than the corresponding S enantiomers in the guinea pig bronchoconstriction assay. A second in vivo model used to evaluate PAF antagonists determines the ability of test compounds to decrease the area of skin wheals induced by an intradermal injection of PAF. In this model, using both rats and guinea pigs, compounds 31 and 58 were found to be as active as the reference PAF antagonist 3-[4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- a][1,4]diazepin-2-yl]-1-(4-morpholinyl)-1-propanone (45).